Thiago Antonio de Sousa Cutrim, Fernando Fontes Barcelos, Leandra Martins Meireles, Poliana Aparecida Rodrigues Gazolla, Ângela Maria Almeida Lima, Róbson Ricardo Teixeira, Luiza Carvalheira Moreira, Vagner Tebaldi de Queiroz, Luiz Cláudio Almeida Barbosa, Pedro Alves Bezerra Morais, Cláudia Jorge do Nascimento, Jochen Junker, Adilson Vidal Costa, Marcio Fronza, Rodrigo Scherer
{"title":"1,2,3-三唑丁香酚衍生物的设计、合成、对接研究和生物活性评估。","authors":"Thiago Antonio de Sousa Cutrim, Fernando Fontes Barcelos, Leandra Martins Meireles, Poliana Aparecida Rodrigues Gazolla, Ângela Maria Almeida Lima, Róbson Ricardo Teixeira, Luiza Carvalheira Moreira, Vagner Tebaldi de Queiroz, Luiz Cláudio Almeida Barbosa, Pedro Alves Bezerra Morais, Cláudia Jorge do Nascimento, Jochen Junker, Adilson Vidal Costa, Marcio Fronza, Rodrigo Scherer","doi":"10.1080/17568919.2024.2385292","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> The design, synthesis, docking studies and evaluation of the <i>in vitro</i> antifungal and cytotoxic properties of eugenol (EUG) containing 1,2,3-triazole derivatives are reported. Most of the derivatives have not been reported.<b>Materials & methods:</b> The EUG derivatives were synthesized, molecular docked and tested for their antifungal activity.<b>Results:</b> The compounds showed potent antifungal activity against <i>Trichophyton rubrum</i>, associated with dermatophytosis. Compounds <b>2a</b> and <b>2i</b> exhibited promising results, with <b>2a</b> being four-times more potent than EUG. The binding mode prediction was similar to itraconazole in the lanosterol-14-α-demethylase wild-type and G73E mutant binding sites. Additionally, the pharmacokinetic profile prediction suggests good gastrointestinal absorption and potential oral administration.<b>Conclusion:</b> Compound <b>2a</b> is a promising antifungal agent against dermatophytosis caused by <i>T. rubrum</i>.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Design, synthesis, docking studies and bioactivity evaluation of 1,2,3-triazole eugenol derivatives.\",\"authors\":\"Thiago Antonio de Sousa Cutrim, Fernando Fontes Barcelos, Leandra Martins Meireles, Poliana Aparecida Rodrigues Gazolla, Ângela Maria Almeida Lima, Róbson Ricardo Teixeira, Luiza Carvalheira Moreira, Vagner Tebaldi de Queiroz, Luiz Cláudio Almeida Barbosa, Pedro Alves Bezerra Morais, Cláudia Jorge do Nascimento, Jochen Junker, Adilson Vidal Costa, Marcio Fronza, Rodrigo Scherer\",\"doi\":\"10.1080/17568919.2024.2385292\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> The design, synthesis, docking studies and evaluation of the <i>in vitro</i> antifungal and cytotoxic properties of eugenol (EUG) containing 1,2,3-triazole derivatives are reported. Most of the derivatives have not been reported.<b>Materials & methods:</b> The EUG derivatives were synthesized, molecular docked and tested for their antifungal activity.<b>Results:</b> The compounds showed potent antifungal activity against <i>Trichophyton rubrum</i>, associated with dermatophytosis. Compounds <b>2a</b> and <b>2i</b> exhibited promising results, with <b>2a</b> being four-times more potent than EUG. The binding mode prediction was similar to itraconazole in the lanosterol-14-α-demethylase wild-type and G73E mutant binding sites. Additionally, the pharmacokinetic profile prediction suggests good gastrointestinal absorption and potential oral administration.<b>Conclusion:</b> Compound <b>2a</b> is a promising antifungal agent against dermatophytosis caused by <i>T. rubrum</i>.</p>\",\"PeriodicalId\":12475,\"journal\":{\"name\":\"Future medicinal chemistry\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-08-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future medicinal chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17568919.2024.2385292\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17568919.2024.2385292","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Design, synthesis, docking studies and bioactivity evaluation of 1,2,3-triazole eugenol derivatives.
Aim: The design, synthesis, docking studies and evaluation of the in vitro antifungal and cytotoxic properties of eugenol (EUG) containing 1,2,3-triazole derivatives are reported. Most of the derivatives have not been reported.Materials & methods: The EUG derivatives were synthesized, molecular docked and tested for their antifungal activity.Results: The compounds showed potent antifungal activity against Trichophyton rubrum, associated with dermatophytosis. Compounds 2a and 2i exhibited promising results, with 2a being four-times more potent than EUG. The binding mode prediction was similar to itraconazole in the lanosterol-14-α-demethylase wild-type and G73E mutant binding sites. Additionally, the pharmacokinetic profile prediction suggests good gastrointestinal absorption and potential oral administration.Conclusion: Compound 2a is a promising antifungal agent against dermatophytosis caused by T. rubrum.
期刊介绍:
Future Medicinal Chemistry offers a forum for the rapid publication of original research and critical reviews of the latest milestones in the field. Strong emphasis is placed on ensuring that the journal stimulates awareness of issues that are anticipated to play an increasingly central role in influencing the future direction of pharmaceutical chemistry. Where relevant, contributions are also actively encouraged on areas as diverse as biotechnology, enzymology, green chemistry, genomics, immunology, materials science, neglected diseases and orphan drugs, pharmacogenomics, proteomics and toxicology.